logo
Plus   Neg
Share
Email

Regeneron Pharma Reports Positive Phase 3 Results For Evinacumab - Quick Facts

Regeneron Pharmaceuticals, Inc. (REGN) said a Phase 3 study of evinacumab in patients with homozygous familial hypercholesterolemia met its primary endpoint. In the trial, the investigational angiopoietin-like 3 antibody, when added to other lipid-lowering therapies, decreased LDL cholesterol by 49% on average, compared to lipid-lowering therapies alone. In the study, evinacumab was well-tolerated.

The company said the detailed results from the trial will be presented at a future medical meeting. Data will be submitted to regulatory authorities, with the FDA in 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A New York regulator has launched an investigation into the credit card practices of Goldman Sachs Group Inc. for alleged gender discrimination in determining limits for Apple's new credit card, which is administered by Goldman Sachs. The Apple Card, Apple's first credit card, was introduced by the tech giant in March this year in partnership with Goldman Sachs and Mastercard. The U.S. Food and Drug Administration approved the first therapy for patients with a rare inherited blood disorder called beta thalassemia. Celegene's Reblozyl is also the first and only FDA-approved erythroid maturation agent, a new class of therapy for such patients. The regulator approved Reblozyl for treating anemia in adult patients with beta thalassemia who require regular RBC transfusions. McDonald's is adding renewable energy to the grid, as part of its efforts to address climate change. The fast-food giant said it signed two long-term, large-scale virtual power purchase agreements or VPPAs to buy renewable energy generated by wind and solar power. Under the agreements, McDonald's will buy a combined 380MW in renewable energy.
Follow RTT
>